Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$598.76 +29.85 (+5.25%)

As of 04:00 PM Eastern

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
4

Buy
21

Based on 26 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 4 have given a hold rating, 18 have given a buy rating, and 3 have given a strong buy rating for REGN.

Consensus Price Target

$912.20
52.35% Upside

According to the 26 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $912.20. The highest price target for REGN is $1,300.00, while the lowest price target for REGN is $150.00. The average price target represents a forecasted upside of 52.35% from the current price of $598.76.

Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

REGN Analyst Ratings Over Time

Type	Current Forecast 4/30/24 to 4/30/25	1 Month Ago 3/31/24 to 3/31/25	3 Months Ago 1/31/24 to 1/30/25	1 Year Ago 5/1/23 to 4/30/24
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	16 Buy rating(s)	14 Buy rating(s)	15 Buy rating(s)
Hold	4 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$912.20	$966.88	$1,004.57	$977.77
Forecasted Upside	52.35% Upside	52.45% Upside	47.06% Upside	9.78% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	61.95% Upside	3,330.71% Upside	21.03% Upside
News Sentiment Rating	Positive News See Recent REGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/30/2025	Truist Financial 2 of 5 stars	Srikripa Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$975.00 ➝ $940.00	+58.66%
4/30/2025	The Goldman Sachs Group 3 of 5 stars	Salveen Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$917.00 ➝ $804.00	+36.25%
4/30/2025	Wells Fargo & Company 3 of 5 stars	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$750.00 ➝ $700.00	+19.35%
4/30/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$1,051.00 ➝ $943.00	+60.78%
4/30/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$865.00 ➝ $800.00	+37.68%
4/30/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$768.00 ➝ $633.00	+9.41%
4/25/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Skorney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$759.00 ➝ $652.00	+8.71%
4/22/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Newman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/22/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$695.00	+23.78%
4/17/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Underperform ➝ Underperform	$575.00 ➝ $547.00	-0.42%
Get the Latest News and Ratings for REGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
3/31/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$1,100.00 ➝ $1,000.00	+57.72%
2/5/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/5/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$762.00 ➝ $834.00	+19.65%
2/4/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$1,230.00 ➝ $1,030.00	+48.22%
2/4/2025	Bernstein Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$1,070.00 ➝ $1,000.00	+44.18%
1/28/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$795.00 ➝ $750.00	+9.54%
1/27/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$1,195.00 ➝ $1,013.00	+47.20%
1/7/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,110.00 ➝ $1,070.00	+47.03%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,150.00	+46.96%
11/6/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,150.00 ➝ $1,000.00	+20.56%
11/1/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,235.00 ➝ $1,184.00	+41.27%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,080.00 ➝ $1,065.00	+25.91%
10/24/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$1,250.00 ➝ $1,175.00	+24.93%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,180.00 ➝ $1,300.00	+19.90%
6/25/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,060.00 ➝ $1,170.00	+9.97%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	+17.00%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$800.00	-2.77%
11/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$950.00	+16.02%
9/15/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
6/28/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$976.00 ➝ $895.00	+17.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:57 PM ET.

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 23, 2025. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

The current stock price is around $587.85, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
Regeneron Pharmaceuticals, Inc. reported a strong quarterly earnings performance, with earnings per share (EPS) of $12.07, exceeding analysts' expectations, indicating robust financial health.
The company has a high net margin of over 31%, suggesting efficient management and profitability, which can be attractive to investors seeking stable returns.
With a return on equity of 16.32%, Regeneron Pharmaceuticals, Inc. demonstrates effective use of shareholder equity to generate profits, a key indicator of financial performance.
Institutional investors hold a significant portion of the company's stock, indicating confidence in its future growth potential and stability.

Regeneron Pharmaceuticals
Bear Case

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

The stock has experienced a decline from its 52-week high of $1,211.20, which may raise concerns about its current valuation and future performance.
Analysts have recently lowered their price targets for the stock, indicating a potential lack of confidence in its short-term growth prospects.
The company has a PEG ratio of 2.34, which suggests that the stock may be overvalued relative to its earnings growth rate, a consideration for value-focused investors.
Despite a strong quarterly performance, the overall market sentiment may be cautious due to broader economic factors affecting the biopharmaceutical industry.
Regeneron Pharmaceuticals, Inc. has a relatively low dividend yield of 0.60%, which may not appeal to income-focused investors looking for higher returns from dividends.

REGN Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $912.20, with a high forecast of $1,300.00 and a low forecast of $150.00.
: 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 4 hold ratings, 18 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares.
: According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 52.35% based on their 12-month stock forecasts.
: Over the previous 90 days, Regeneron Pharmaceuticals's stock had 3 upgrades by analysts.
: Regeneron Pharmaceuticals has been rated by research analysts at Bank of America, Bernstein Bank, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Robert W. Baird, Royal Bank of Canada, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Regeneron Pharmaceuticals more than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how REGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:REGN) was last updated on 4/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target